NBTX Nanobiotix S.A.
Stock Price & Overview

$5.21-0.013 (-0.25%)9:59 AM 07/17/25
NASDAQ | $USD | Delayed

NBTX Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

NBTX Analysis

NBTX News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Similar to NBTX

ETFs Holding NBTX

NBTX Company Profile

Nanobiotix S.A. logo
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Sector
Health Care
Industry
Biotechnology
Employees
108
Founded
2003
Address
  • 60 rue de Wattignies
  • Paris, 75012
  • France
Phone Number
33 1 40 26 04 70
Website
www.nanobiotix.com
Hide

NBTX Revenue

More On Revenue »

Earnings Estimates

Earnings Revisions

Profitability

Momentum

Capital Structure

Dividends

NBTX does not currently pay a dividend.

NBTX Ownership

NBTX Peers

Risk

Technicals

NBTX Transcripts

Investor Presentations

NBTX SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

NBTX Income Statement

NBTX Balance Sheet

NBTX Cash Flow Statement

NBTX Long Term Solvency

Nanobiotix S.A. (NBTX) Frequently Asked Questions